Senate Report Scrutinizes Schultz’ Role In Cyberonics’ Device Approval

A Senate Finance Committee report scrutinizes CDRH Director Daniel Schultz' role in FDA's controversial decision to approve Cyberonics' VNS Therapy neurostimulation device for treatment-resistant depression (TRD) in July 2005